Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy
September 20, 2024,TOKYO, Japan : Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in …